TY  - GEN
AU  - Chen,Jiaying
AU  - Ji,Qinghai
AU  - Bai,Chunmei
AU  - Zheng,Xiangqian
AU  - Zhang,Yuan
AU  - Shi,Feng
AU  - Li,Xiaojiang
AU  - Tang,Pingzhang
AU  - Xu,Zhengang
AU  - Huang,Rui
AU  - Huang,Tao
AU  - Pan,Yueyin
AU  - Fan,Songhua
AU  - Zhou,Jinghong
AU  - Su,Weiguo
TI  - Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
SN  - 1557-9077
PY  - 2021///1105
KW  - Adult
KW  - Aged
KW  - Biomarkers
KW  - blood
KW  - Calcitonin
KW  - Carcinoma, Neuroendocrine
KW  - drug therapy
KW  - Cell Differentiation
KW  - China
KW  - epidemiology
KW  - Female
KW  - Humans
KW  - Indoles
KW  - therapeutic use
KW  - Iodine Radioisotopes
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Pyrimidines
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - metabolism
KW  - Sulfonamides
KW  - Thyroid Neoplasms
KW  - Time Factors
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1089/thy.2019.0453
ER  -